BLUE

bluebird bio Inc

Healthcare


Presented:10/09/2015
Price:$88.80
Cap:$2.93B
Current Price:$0.48
Cap:$0.09B

Presented

Date10/09/2015
Price$88.80
Market Cap$2.93B
Ent Value$4.74B
P/E RatioN/A
Book Value$25.56
Div Yield0%
Shares O/S32.96M
Ave Daily Vol926,953
Short Int9.14%

Current

Price$0.48
Market Cap$0.09B
bluebird bio, Inc. is a clinical-stage biotechnology company. The company develops next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. It has two clinical-stage programs in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease and a preclinical oncology program in the chimeric antigen receptor T cells field. bluebird bio was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Publicly traded companies mentioned herein: Bellicum Pharmaceuticals Inc (BLCM), bluebird bio Inc (BLUE), Celgene Corporation (CELG), Global Blood Therapeutics Inc (GBT), Juno Therapeutics Inc (JUNO)

Highlights

Despite a substantial decline from the $190s to $90, the presenter believes shares of bluebird (BLUE ) - “one of the most beloved gene therapy stocks” - are still overvalued. The company is presently flush with cash, but is burning it quickly and the share count is expanding rapidly. Among the red flags he sees are: in August 2015, BLUE executives sold “tons of stock;” there is competition on the horizon for BLUE’s most valuable development program [LentiGlobin, which is in trials for beta-thalassemia and Sickle Cell Disease (SCD)], and in the presenter’s opinion there is the potential for data to fall short of expectations this December at the American Society of Hematology’s (ASH) annual meeting (12/5 - 12/8). If his concerns prove to be well-founded shares of BLUE are likely worth closer to $40/ share.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.